Actively Recruiting
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Led by Pfizer · Updated on 2026-05-08
260
Participants Needed
9
Research Sites
224 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This study is seeking participants that have advanced or metastatic breast cancer (BC), or advanced or metastatic colorectal cancer (CRC). All participants in this study will take the study medication (PF-08032562) as pill by mouth. This will be repeated for 28-day cycles. Depending on which part of the study participants are enrolled into, they will receive the study medication PF-08032562 alone or in combination with other anti-cancer medications. The study medication (PF-08032562) will be taken by mouth (PO) in combination with other anti-cancer medications given in the study clinic by intramuscular (IM) injection into the muscle or intravenous (IV) infusion that is directly injected into the veins at different times (depending on the treatment) during the 28-day cycle. The study may also test different schedules.
CONDITIONS
Official Title
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Advanced or metastatic breast or colorectal cancer
- For breast cancer: disease progression after at least 1 line of endocrine therapy and CDK4/6 inhibitor in advanced/metastatic setting (varies by study part)
- For colorectal cancer: prior chemotherapy and/or targeted therapy if appropriate (varies by study part)
- Measurable disease
- ECOG performance status 0 or 1
You will not qualify if you...
- Active malignancy within 3 years prior to enrollment
- Known symptomatic brain metastases requiring steroids
- Advanced/metastatic symptomatic visceral spread with risk of life-threatening complications shortly
- Prior irradiation to more than 25% of bone marrow
- Uncontrolled hypertension
- Renal impairment
- Hepatic dysfunction
- Cardiac abnormalities
- Active bleeding disorder
- Active or history of significant gastrointestinal disease
- Other unacceptable abnormalities as defined by protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California, United States, 91010
Actively Recruiting
2
START Midwest, LLC
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
3
The University of Texas MD Anderson Cancer Center - Conroe
Conroe, Texas, United States, 77384
Actively Recruiting
4
The University of Texas - M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
5
The University of Texas, MD Anderson Cancer Center - West Houston
Houston, Texas, United States, 77079
Actively Recruiting
6
The University of Texas, MD Anderson Cancer Center - League City
League City, Texas, United States, 77573
Actively Recruiting
7
START San Antonio
San Antonio, Texas, United States, 78229
Actively Recruiting
8
The University of Texas, MD Anderson Cancer Center - Sugar Land
Sugar Land, Texas, United States, 77478
Actively Recruiting
9
START Mountain Region
West Valley City, Utah, United States, 84119
Actively Recruiting
Research Team
P
Pfizer CT.gov Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here